Sun Pharmaceutical Industries Inc. v. Biofrontera Bioscience GmbH

This is a Post-Grant Review (PGR) proceeding initiated by Sun Pharmaceutical Industries Inc. against Biofrontera Bioscience GmbH before the Patent Trial and Appeal Board (PTAB) concerning U.S. Patent No. 12280146. Sun Pharmaceutical Industries Inc. is a major Indian multinational pharmaceutical company, known for manufacturing and selling a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs), including generics and innovative medicines, with a significant global and U.S. market presence across various therapeutic areas like dermatology. Biofrontera Bioscience GmbH, a subsidiary of the German biopharmaceutical company Biofrontera AG, specializes in the development and sale of dermatological drugs, particularly focusing on photodynamic therapy (PDT) for skin conditions such as actinic keratosis.

The patent at issue, U.S. Patent No. 12280146, is described as a "topical ALA nanoemulsion patent." This patent likely covers formulations of 5-aminolevulinic acid (ALA) in a nanoemulsion for topical application, which is a key component in photodynamic therapy treatments. Sun Pharmaceutical is challenging the patentability of this patent, asserting grounds of anticipation and obviousness against all 17 of its formulation claims. This PGR is being heard by the Patent Trial and Appeal Board, an administrative body within the U.S. Patent and Trademark Office, where the patent's validity can be challenged based on a broad range of prior art and statutory grounds. The case was filed on January 16, 2026, and is currently pending before the PTAB.

This PGR is notable as it forms part of a larger, ongoing intellectual property dispute between Sun Pharmaceutical and Biofrontera in the dermatology and photodynamic therapy market. Previously, in June 2024, Sun Pharmaceutical initiated patent infringement lawsuits against Biofrontera in the U.S. District Court for the District of Massachusetts and the International Trade Commission, alleging infringement of its own patents, specifically U.S. Patent Nos. 11,697,028 and 11,446,512. In response, Biofrontera filed inter partes reviews (IPRs) challenging Sun Pharma's patents, and as of February 2026, the PTAB found all challenged claims of Sun Pharma's U.S. Patent No. 11,697,028 unpatentable. This current PGR suggests that Sun Pharmaceutical is now challenging Biofrontera's patents, indicating a complex and multi-faceted legal battle over key technologies and market share in the treatment of dermatological conditions like actinic keratosis. The outcome of this PGR could have significant implications for both companies' commercial strategies and competitive positioning in the photodynamic therapy space.

This is a Post-Grant Review (PGR) proceeding, PGR2026-00021, initiated by Sun Pharmaceutical Industries Inc. against Biofrontera Bioscience GmbH (also referred to as Biofrontera Inc. in some filings) before the Patent Trial and Appeal Board (PTAB) concerning US Patent No. 12,280,146. The case was filed on January 16, 2026, and is currently pending.

Due to the relatively recent filing date, many of the typical litigation milestones for a district court case, such as discovery, Markman hearings, or trial events, are not applicable in a PGR, or have not yet occurred within the PTAB's expedited timeline.

Here are the key legal developments to date:

• Filing & Initial Pleadings (PGR Petition):

  • 2026-01-16: Sun Pharmaceutical Industries Inc. filed a Petition for Post-Grant Review (PGR) challenging US Patent No. 12,280,146. In a PGR, the petition serves as the initial pleading, outlining the grounds on which the patent claims are alleged to be unpatentable.
  • The Patent Owner, Biofrontera Bioscience GmbH, has a period of three months from the filing of the petition to submit an optional preliminary response arguing against the institution of the review.

• Pre-institution Motions of Substance:

  • No information on specific pre-institution motions (e.g., motions to deny institution) is publicly available at this stage, beyond the typical Patent Owner Preliminary Response period.

• Claim Construction:

  • The PTAB, at the institution stage of a PGR, typically interprets claims using the broadest reasonable interpretation (BRI) consistent with the specification. A more formal claim construction decision would generally occur if the case proceeds to a trial phase. It is too early for a formal claim construction outcome in this proceeding.

• Institution Decision:

  • The PTAB is required to decide whether to institute the PGR within six months of the petition filing date. Therefore, a decision on institution for PGR2026-00021 is expected by approximately July 16, 2026. The PGR will be instituted if the PTAB determines that it is "more likely than not" that at least one of the challenged claims is unpatentable.

• Discovery Milestones, Trial Events, Verdict, Post-Trial Motions:

  • These stages would only occur if the PGR is instituted by the PTAB. Given the filing date of January 16, 2026, the case has not progressed to these stages.

• Settlement, Dismissal, Judgment, or Appeal:

  • The case is currently pending, awaiting an institution decision. No final judgment, settlement, or appeal has occurred for this specific PGR.

• Parallel PTAB IPR/PGR Proceedings on the Asserted Patents:

  • While this specific PGR concerns US Patent No. 12,280,146, there have been other recent PTAB proceedings between these parties involving different patents. Biofrontera Inc. successfully challenged Sun Pharmaceutical Industries Inc.'s US Patent No. 11,697,028 through an Inter Partes Review (IPR). On February 23, 2026, the PTAB issued a Final Written Decision finding all challenged claims of that patent unpatentable. Additionally, Biofrontera filed an IPR petition against Sun Pharma's US Patent No. 11,446,512, which was denied review on administrative grounds. These parallel proceedings highlight an ongoing intellectual property dispute between Sun Pharmaceutical and Biofrontera. There is no indication of other IPRs or PGRs specifically targeting US Patent No. 12,280,146.

Sun Pharmaceutical Industries Inc. is represented by attorneys from Desmarais LLP in the Post-Grant Review (PGR) proceeding PGR2026-00021.

The counsel of record identified for the plaintiff, Sun Pharmaceutical Industries Inc., include:

• Yung-Hoon Ha

  • Role: Attorney for Petitioner
  • Firm: Desmarais LLP
  • Office Location: Specific office location for Yung-Hoon Ha at Desmarais LLP is not provided in the search results, but Desmarais LLP has offices in New York.
  • Relevant Experience: Yung-Hoon Ha is listed as an attorney for Sun Pharmaceutical Industries Inc. in this PGR.

• Bridget P. Belcher

  • Role: Attorney for Petitioner
  • Firm: Desmarais LLP
  • Office Location: Specific office location for Bridget P. Belcher at Desmarais LLP is not provided in the search results, but Desmarais LLP has offices in New York.
  • Relevant Experience: Bridget P. Belcher is listed as an attorney for Sun Pharmaceutical Industries Inc. in this PGR.

Although other attorneys from Carlson Caspers Vandenburgh & Lindquist (J. Derek Vandenburgh, Samuel T. Lockner, Alexandra J. Olson, and Peter M. Kohlhepp) have represented Sun Pharmaceutical Industries Inc. in a separate Inter Partes Review (IPR2025-00893), they are not listed as counsel for the petitioner in the specific PGR2026-00021 case against Biofrontera Bioscience GmbH. Therefore, Desmarais LLP appears to be the primary firm representing Sun Pharmaceutical Industries Inc. in this particular PGR.

Counsel of Record for Biofrontera Bioscience GmbH

In the ongoing Post-Grant Review (PGR) proceeding PGR2026-00021, Biofrontera Bioscience GmbH is represented by counsel from Polsinelli PC. While initial docket summaries for this PTAB case indicated "No Attorneys" for the Respondent, subsequent filings on the docket show the appearance of counsel.

The identified attorney representing Biofrontera Bioscience GmbH is:

• Name: Brian J. Larivee
• Role: Counsel
• Firm: Polsinelli PC
• Office Location: Boston, Massachusetts (Based on firm profile; not explicitly stated for this case, but Polsinelli has a Boston office and Larivee's move to Polsinelli's Boston office was in early 2024/2026).
• Relevant Patent Litigation Experience: Brian J. Larivee is a trial lawyer with over 15 years of experience in patent and intellectual property litigation, particularly for biotechnology, pharmaceutical, and medical device companies. He has experience leading high-profile litigation campaigns, including Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) matters, before federal district courts, the International Trade Commission (ITC), the U.S. Patent and Trademark Office (including PTAB), the Federal Circuit, and the U.S. Supreme Court. Larivee also brings a global perspective to patent litigation strategy, having navigated cross-border disputes and managed patent defense strategies for biosimilar products in European patent litigation. He joined Polsinelli as counsel in the Intellectual Property Department and the Hatch-Waxman and Biologics Practice in early 2024/2026.

Note on Filings: A "Notice of Intent Designate Brian Larivee" was filed by the Patent Owner (Biofrontera Bioscience GmbH) on February 11, 2026, following a "Notice: Power of Attorney" on February 9, 2026, in PGR2026-00021. Biofrontera Bioscience GmbH has also been represented by Polsinelli PC in other intellectual property-related proceedings, such as an ITC investigation (Inv. No. 337-TA-1411). As of the current date, no other specific attorneys beyond Brian J. Larivee have been explicitly identified as counsel of record for Biofrontera Bioscience GmbH in PGR2026-00021 through the publicly available information.